原发性肝癌患者血清可溶性白细胞介素2受体水平测定的临床意义

目的 探讨可溶性白细胞介素２受体（ｓＩＬ－２Ｒ）在原发性肝癌（ＰＬＣ）患者中的临床意义。方法 采用双抗体夹心ＥＬＩＳＡ法检测对照组４０例,健康献血员和疾病组１０５例ＰＬＣ患者血清ｓＩＬ－２Ｒ水平（其中Ⅰ、Ⅱ、Ⅲ期肝癌患者分别为２２例、４１例、４２例）以及１８例切除肿瘤后和１８例栓塞化疗（ＴＡＥ）后动态检测观察。结果 ＰＬＣ患者血清ｓＩＬ－２Ｒ水平依次增高（Ｐ〈０．０１）;ｓＩＬ－２Ｒ水平〉１０００     

胃癌患者中sIL—2R表达的临床意义

采用ＥＬＩＳＡ法检测５２例胃癌患者及２０例健康人的血清ｓＩＬ－２Ｒ浓度，结果发现：胃癌患者血清ｓＩＬ－２Ｒ水平明显高于健康对照组（Ｐ〈０．０１）。伴有转移者的ｓＩＬ－２Ｒ升高更明显，与无转移者相比，差异显著（Ｐ〈０．０１），胃癌术后ｓＩＬ－２Ｒ升高提示有复发可能。     

恶性淋巴瘤患者脑脊液可溶性白细胞介素2受体水平的动态观？…

用双抗体夹心ＥＬＩＳＡ方法动态监测４６例恶性淋巴瘤（ＭＬ）患者脑脊液（ＣＳＦ）中可溶性白细胞介素２受体（ｓＩＬ－２Ｒ）水平变化。发现ＭＬ患者脑脊液中ｓＩＬ－２Ｒ比正常人显著升高（Ｐ〈０．００１），且６例有中枢神经系统（ＣＮＳ）浸润者ｓＩＬ－２Ｒ与无ＣＮＳ浸润者相比有显著性差异（Ｐ〈０．０１）；而治疗达ＣＲ或ＰＲ后ｓＩＬ－２Ｒ显著降低（Ｐ〈０．０５），与正常人者相比Ｐ〉０．０５，脑脊液ｓＩＬ－２Ｒ水     

喉癌患者血清可溶性白细胞介素2受体（sIL—2R）的表达及其意义

应用双抗体夹心ＥＬＩＳＡ方法测定了３０例喉癌患者血清可溶性白细胞介素２受体（ｓＩＬ－２Ｒ）水平。结果表明：喉癌患者血清ｓＩＬ－２Ｒ水平明显高于正常人（Ｐ〈０．０１）；与临床分期有关，病期越晚，ｓＩＬ－２Ｒ水平越高；ｓＩＬ－２Ｒ水平超过１０００Ｕ／ｍｌ者，多预后不良；９例术后２￣８月再次采血检验，６例无癌生存者ｓＩＬ－２Ｒ水平明显下降（Ｐ〈０．０１），３例复发的患者血清ｓＩＬ－２Ｒ升高。提示：喉癌患     

喉癌患者血清可溶性白细胞介素2受体（sIL－2R）的表达及其意义

应用双抗体夹心ＥＬＩＳＡ方法测定了３０例喉癌患者血清可溶性白细胞介素２受体（ＳＩＬ－ＺＲ）水平。结果表明：喉癌患者血清ＳＩＬ－ＺＲ水平明显高于正常人（Ｐ＜０．０１）；与临床分期有关，病期越晚，ｓＩＬ－２Ｒ水平越高；ｓＩＬ－２Ｒ水平超过１０００Ｕ／ｍｌ者，多预后不良；９例术后２～８月再次采血检验，６例无癌生存者ｓＩＬ－２Ｒ水平明显下降（Ｐ＜０．０１），３例复发的患者血清ｓＩＬ－２Ｒ升高。提示：喉癌患者血清ｓＩＬ－２Ｒ的测定对预后判断和疗效观察有重要意义。     

胃癌患者可溶性白介素—2受体测定及其意义

本文应用双抗体夹心直接ＥＬＩＳＡ法对３６例胃癌患者血清ＳＩＬ－２Ｒ水平进行了测定。胃癌患者血清ＳＩＬ－２Ｒ水平明显高于正常人群（Ｐ〈０．０１）及慢性良性胃病患者（Ｐ〈０．００１）；Ⅲ－Ⅳ期患者血清ＳＩＬ－２Ｒ水平明显高于Ⅰ－Ⅱ期患者（Ｐ〈０．０１）：胃癌根治后１０天血清ＳＩＬ－２Ｒ水平较术前明显下降（Ｐ〈０．０１），与正常人群对照无明显差异（Ｐ〈０．０５）。结果说明血清ＳＩＬ－２Ｒ测定可作为胃癌的     

胃癌患者血清中sIL－2R水平及其临床意义

通过采用ｓＩＬ－２Ｒ单克隆抗体（ＭｃＡｂ）建立了可溶性ＩＬ－２Ｒ（ｓＩＬ－２Ｒ）的双夹心ＥＬＩＳＡ法，检测了１６１倒Ⅲ～Ⅳ期胃癌患者在手术前后、复发或转移及８０例单纯化疗后血清中ｓＩＬ－２Ｒ变化。结果表明：晚期胃癌患者血清中ｓＩＬ－２Ｒ水平显著高于正常人（Ｐ＜０．０１），在有转移或术后复发时，ｓＩＬ－２Ｒ水平显著升高，ｓＩＬ－２Ｒ＜１０００Ｕ／ｍｌ患者三年生存率显著高于＞１０００Ｕ／ｍｌ者；化疗有效者，ｓＩＬ－２Ｒ可明显下降，无效者则无明显改变，提示晚期胃癌患者ｓＩＬ－２Ｒ水平对判断预后有重要临床价值。     

检测非小细胞肺癌IL—2R的临床意义

目的 探讨检测血清可溶性白细胞介素２受体（ＳＩＬ－２Ｒ）和肺癌组织ＩＬ－２Ｒ表达在非小细胞肺癌中的临床意义。方法 采用双抗体夹心ＥＬＩＳＡ法和免疫组化法检测４２例非小细胞肺癌患者血清和肺癌组织中ＩＬ－２Ｒ水平。结果 肺癌患者血清ＳＩＬ－２Ｒ水平显著高于正常人（Ｐ〈０．０５），Ⅲ，Ⅳ期肺癌患者血清ＳＩＬ－２Ｒ水平显著高于Ⅰ，Ⅱ期（Ｐ〈０．０５），但血清ＳＩＬ－２Ｒ水平与肺癌组织学类型无明显关系（Ｐ〉     

恶性淋巴瘤患者脑脊液可溶性白细胞介素2受体水平的动态观察及其临床意义

用双抗体夹心ＥＬＩＳＡ方法动态监测４６例恶性淋巴瘤（ＭＬ）患者脑脊液（ＣＳＦ）中可溶性白细胞介素２受体（ｓＩＬ－２Ｒ）水平变化。发现ＭＬ患者脑脊液中ｓＩＬ－２Ｒ比正常人显著升高（Ｐ＜０．００１），且６例有中枢神经系统（ＣＮＳ）浸润者ｓＩＬ－２Ｒ与无ＣＮＳ浸润者相比有显著性差异（Ｐ＜０．０１）；而治疗达ＣＲ或ＰＲ后ｓＩＬ－２Ｒ显著降低（Ｐ＜０．０５），与正常人者相比Ｐ＞０．０５，脑脊液ｓＩＬ－２Ｒ水平与血清中ｓＩＬ－２Ｒ水平无显著相关性。认为动态监测ＭＬ患者脑脊液ｓＩＬ－２Ｒ水平有助于估价病变严重程度、ＣＮＳ有无浸润及疗效评定     

肺癌患者IL－2RmRNA表达的临床意义

制备了人ＩＬ－２ＲａｃＤＮＡ探针，采用斑点印迹杂交法对４６例肺癌患者外周血单个核细胞（ＰＢＭＣ）ＩＬ－２ＲｍＲＮＡ的表达水平进行研究。结果发现ＩＬ－２ＲｍＲＮＡ的表达程度与肿瘤转移关系密切。肺癌无转移组：ＩＬ－２ＲｍＲＮＡ表达显著高于对照组与转移组（Ｐ＜０．００１），且与患者的组织学类型及病期有明显关系。转移组：ＩＬ－２Ｒ表达显著低于对照组（Ｐ＜０．００１），提示此组病人存在免疫抑制．其抑制可能存在细胞活化阶段或ＩＬ－２Ｒ的转录水平。同期所测血清肿瘤坏死因子（ＴＮＦ）在两组患者无明显差异。本组结果提示：ＩＬ－２ＲｍＲＮＡ表达水平与患者预后密切相关。     

大肠癌患者血清IAP、sIL-2R和IL-12变化

[目的]探讨检测血清IAP、sIL鄄2R和IL鄄12含量在大肠癌的辅助诊断、预后判断中的临床意义。[方法]采用单向免疫扩散法和ELISA法分别检测30例健康正常人及32例大肠癌患者手术前、后的血清IAP、sIL鄄2R和IL鄄12水平。[结果](1)大肠癌患者手术前血清IAP、sIL鄄2R水平均明显高于对照组(P<0.001和P<0.01),晚期组血清IAP、sIL鄄2R水平明显高于早期组(P<0.02和P<0.05),IAP与sIL鄄2R水平呈显著正相关(r=0.987,P<0.001);大肠癌患者血清IL鄄12水平明显低于对照组(P<0.05)。(2)串联IAP、sIL鄄2R两指标筛检大肠癌的敏感性为78.1%,特异性为93.33%,并联两指标筛检大肠癌,其敏感性为93.75%,特异性为73.3%。(3)手术后患者血清IAP、sIL鄄2R水平均明显低于手术前(P<0.001),早期组下降有明显差异性(P<0.001),而晚期组下降不明显(P>0.1);患者术后血清IL鄄12水平明显比术前升高(P<0.02),早期组上升显著(P<0.001),晚期组上升不明显(P>0.05)。[结论](1)检测患者血清IAP、sIL鄄2R水平对大肠癌的辅助诊断、病情判断、手术治疗和预后观察均有较高的临床价值。(2)联合检测血清IAP、sIL鄄2R对筛检大肠癌患者具有较高的敏感性。(3)血清IAP、sIL鄄2R和IL鄄12可作为指导大肠癌患者免疫学治疗较客观的指标。     

结直肠癌患者血清中IL-17和IL-6的表达及其临床意义

目的:研究结直肠癌(colorectal carcinoma,CRC)患者血清中白细胞介素17(interleukin 17,IL-17)和IL-6的表达,探讨IL-17和IL-6与CRC发生和发展之间的关系.方法:采用ELISA方法检测56例CRC患者和30例健康志愿者(对照组)血清IL-17和IL-6的变化,分析IL-17和IL-6与CRC患者各临床病理特征之间的关系.结果:56例CRC患者血清IL-17为96.43±21.15 ng/L,IL-6为139.53±27.84 ng/L,均明显高于对照组(IL-17为16.88±5.07 ng/L,IL-6为39.21±7.46 ng/L,P＜0.01);IL-17和IL-6水平的上升与患者的性别和年龄无关(P＞0.05),而与肿瘤的大小、远处转移、Dukes分期及病理组织学分型明显相关(P＜0.01).结论:CRC患者血清中IL-17和IL-6水平随着肿瘤的进展而明显上升,预示IL-17和IL-6直接或间接参与了CRC的发生和发展.     

原发性肝癌患者可溶性IL—2受体水平,IL—2和NK活性的变化及意义

采用双抗体夹心ELlSA法检测43例原发性肝细胞癌(PHC)病人血清可溶性白细胞介素2受体(sIL-2R)水平,及其外周血单个核细胞(PBMC_s)的白细胞介素2(IL—2)活性和自然杀伤(NK)细胞活性.另将51例慢性乙型活动性肝炎和肝硬化病人做为对照.结果,上述病人血清sIL—2R水平明显升高,IL—2和 NK活性低于正常人,其中PHC的IL—2和NK活性的降低又为显著(P<0.001< O.001).表明PHC病人的细胞免疫功能受损程度最重.检测sIL_2R水平和IL—2活性,可望做为对PHC患者病情分析及判断预后的指标.     

多发性骨髓瘤IL-6及受体的检测及意义

目的：为了比较不同阶段多发性骨髓瘤（MM）病人血清IL－6及可溶性受体sIL-6R水平与疾病活动性及预后之间的关系。方法；对16名良性骨肿瘤病人，15名多发性骨髓瘤稳定期病人，29名MM进展期及正常人之间血清IL－6,sIL-6R水平进行了比较，采用ELISA方法测定浓度水平，两组间差异采用t检验方法。结果：两指标在各组间存在明显的差异（P＜0．05），同时，在对29名多发性骨髓瘤的随访治疗过程中，18名有效病人的IL－6,sIL-6R在治疗前后存在明显差异，而在无效和死亡的病人中，治疗前后无明显差别。结论：IL－6及sIL-6R水平与疾病的严重程度密切相关，可作为判断病情和预后的一项重要参数。     

氟达拉滨对多发性骨髓瘤细胞系KM3细胞分泌IL-6的影响

目的：研究氟达拉滨（fludarabine）在体外对多发性骨髓瘤细胞KM3细胞生长的影响及对细胞上清液IL-6、sIL-6R的影响。方法：采用MTT法及细胞计数法分别观察不同浓度氟达拉滨对KM3细胞生长的影响；用双抗夹心法检测不同浓度氟达拉滨作用KM3细胞后上清液白细胞介素6（interleukin-6，IL-6）和可溶性白细胞介素6受体（soluble interleukin-6 receptor，sIL-6R）的表达水平。结果：MTT法及细胞计数法均显示氟达拉滨对KM3细胞有明显的抑制作用，氟达拉滨作用KM3细胞72h后，25、50、100、200、400nmol／L组的增殖抑制率均高于对照组（P〈0．01），且与浓度成正比。400nmol/L组对KM3细胞增殖抑制率随时间的延长而增加。双抗夹心法检测结果显示KM3细胞经氟达拉滨作用96h后，其IL-6水平先升高后明显下降，而sIL-6R水平随药物浓度的升高而逐渐下降。结论：氟达拉滨能明显抑制KM3细胞的增殖，同时能抑制KM3细胞自分泌IL-6和sIL-6R。     

Serum Levels of Interleukin-8 and Soluble Interleukin-6 Receptor in Patients with Stage-I Multiple Myeloma: A Case-Control Study

Objective: Multiple myeloma (MM) remains an incurable disease that needs better recognition and further research. Previous studies elucidated the interaction between myeloma cells and showed the necessity of bone marrow stromal cells for the initiation and progression of MM. Many chemokines and their receptors including interleukin-8 (IL-8) and soluble interleukin-6 receptor (sIL-6R) play important roles in this interaction. The main purpose of this study is evaluating the serum level of IL-8 and sIL-6R on stage-I of MM patients and healthy controls. Methods: Serum samples from 30 stage-I MM  patients (13 males and 17 females) and 30 healthy subjects as controls (13 males and 17 females) were examined in this study. The protein concentrations of serum IL-8 and sIL-6R were assessed by enzyme-linked immunosorbent assay (ELISA). Results: The mean level of IL-8 and sIL-6R were significantly elevated in stage-I MM. The mean levels of IL-8 were 1246.57±279.22 ng/ml in stage-I MM and 902.53± 294.61 ng/ml in controls (P<0.001). The mean levels of sIL-6R were 5.39±1.38 ng/ml and 4.1±1.14 ng/ml in stage-I MM and controls, respectively (P<0.001). The mean levels of IL-8 were 1342.18±193.4 ng/ml in patient females and 859± 278.2ng/ml in control females (P <0.001). The mean levels of sIL-6R were 5.21±1.55 ng/ml and 3.91±1.22 ng/ml in patient females and control females, respectively (P=0.01). The mean level of sIL-6R in patient males and control males were 5.63±1.43 ng/ml and 4.34±1.04 ng/ml, respectively (P=0.01). A significant correlation (Pearson’s correlation = 0.45, P=0.008) was observed in the population of females (patients and controls). Conclusion: The results of study suggest the possible involvement of IL-8 and the sIL-6R at stage-I MM and can better characterize the role of chemokines and their receptors in the disease process, especially in the early stages.     

Serum levels of IL-1 beta, sIL-2R, IL-6, IL-8, and TNF-alpha in febrile children with cancer and neutropenia

Serum levels of interleukin-1 beta (IL-1beta), soluble interleukin 2 receptors (sIL-2R), interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor-alpha (TNF-alpha) were measured to predict some characteristics of febrile episodes in children with cancer and neutropenia. Forty-eight episodes of febrile neutropenia were determined in 23 pediatric cancer patients, including 35 febrile episodes without identifiable source, 7 episodes of bacteremia due to Gram-negative organisms and 4 due to Gram-positive organisms, and 2 fungal infections. Interleukin-6, sIL-2R, and IL-8 levels were significantly higher at the beginning of the febrile episodes than those of controls (p < 0.001, p < 0.001, and p < 0.001). Interleukin-6, slL-2R, and IL-8 levels were higher in patients with bacteremia due to Gram-negative organisms than in those with Gram-positive ones (p = 0.042, p = 0.006, and p = 0.023, respectively). TNF-alpha and IL-1beta levels were similar in febrile episodes and controls (p > 0.05). In conclusion, sIL-2R, IL-6, and IL-8 levels may be helpful in the prediction of infection in febrile cancer patients with neutropenia and measurements of IL-1beta and TNF-alpha were not useful for identifying the presence and the type of infection in febrile neutropenic episodes in children.     

CTCL患者外周血淋巴细胞亚群、血清sIL-2R及炎性因子的水平变化特点及意义

目的:探讨皮肤T细胞淋巴瘤（CTCL）患者外周血淋巴细胞亚群及血清可溶性白细胞介素2受体（sIL-2R）、炎性因子的水平变化特点及意义。方法:选取2013年1月至2018年1月在我院治疗的CTCL患者35例（CTCL组）,同时选取炎症性皮肤病患者35例作为对照组,检测两组血清sIL-2R、B淋巴细胞、T淋巴细胞和NK细胞水平以及白细胞介素-6（IL-6）、肿瘤坏死因子 （TNF-α）和C反应蛋白（CRP）。结果:CTCL组血清sIL-2R为（770.15±87.44）U/ml,明显高于对照组（P＜0.05）,而B淋巴细胞为6.10（0.15～10.57）%,明显低于对照组（P＜0.05）;CTCL组和对照组T淋巴细胞和NK细胞比较差异无统计学意义（P＞0.05）;CTCL组血清IL-6、TNF-α和CRP分别为110.02(67.39,230.03)pg/ml、（31.29±7.28）pg/ml和（36.60±6.10）mg/L,明显高于对照组（P＜0.05）;皮损改善患者治疗后sIL-2R为（230.04±78.11）U/ml,明显低于皮损未改善患者（P＜0.05）。结论:CTCL患者血清sIL-2R、IL-6、TNF-α和CRP升高,而B淋巴细胞水平降低,其中sIL-2R与治疗效果有一定关系,值得进一步研究。     

急性髓系白血病患者化疗后血清IL-8、IL-6水平与感染的关系

目的：探讨急性髓系白血病(AML)患者化疗后粒细胞缺乏发热时血清白细胞介素8(IL-8)和白细胞介素6(IL-6)水平与感染的关系。方法：采用双抗体夹心酶联免疫吸附法(ELISA)检测42例AML患者和20名正常对照者血清IL-8、IL-6水平。结果：血清IL-8和IL-6水平在AML患者发热第1天均升高，其中病原学检查阳性组显著高于原因不明发热组(P均＜0.002)和仅有临床感染证据组(P均＜0.05)，仅有临床感染证据组也较原因不明发热组增高(P均＜0.02)，且革兰氏阴性菌感染者较革兰氏阳性菌感染者增高明显(P均＜0.01)；IL-8和IL-6呈显著正相关(r=0.841，P＜0.001)，并均与体温呈正相关(r=0.447和0.570，P＜0.005和P＜0.001)；并发败血症死亡患者的血清IL-8、IL-6水平呈持续增高。结论：应用夹心法ELISA联合检测血清IL-8、IL-6水平，将有助于确定AML患者化疗后粒细胞缺乏发热时的早期感染及其严重性。     

Prognostic value of serum biological markers in patients with hepatocellular carcinoma.

PURPOSE: Prognosis of patients with hepatocellular carcinoma (HCC) is assessed by using indexes based on clinical and instrumental parameters. The Cancer of the Liver Italian Program (CLIP) staging system combines the Child-Pugh classification with tumor size, portal invasion, and alpha-fetoprotein and predicts the outcome of HCC patients more precisely than the Okuda staging system. Serum levels of a number of biological variables have been found to be increased in patients with HCC and are associated with different outcomes. Our aims in this study were to test the prognostic role of the serum levels of soluble intercellular adhesion molecule-1 (sICAM-1), soluble interleukin-2 receptor (sIL-2R), interleukin 6 (IL-6), and anti-p53 and to assess whether the addition of any of the above serum markers could further improve the predictive ability of the CLIP score. EXPERIMENTAL DESIGN: Serum levels of sICAM-1, sIL-2R, IL-6, and anti-p53 were assayed in 80 patients with HCC and correlated with their outcomes. Nonparametric procedures were applied to test correlations between serum sICAM-1, sIL-2R, IL-6, anti-p53, and other prognostic factors. For survival analyses, the product-limit method, log-rank test, and Cox proportional hazards model were applied. RESULTS: Only serum levels of sIL-2R correlated with survival, which was longer for patients with lower values (< or =950 units/ml). However, with multivariate analysis sIL-2R did not confirm its predictive role when tested with the CLIP score as a covariate, with a hazard of death of 1.51 (95% confidence interval, 0.76-3.01). CONCLUSIONS: Serum levels of sICAM-1, sIL-2R, IL-6, and anti-p53 are not useful as prognostic factors for HCC in clinical practice. They do not improve the predictive ability of the CLIP score.